michael stahl on behalf of the german oesophageal cancer study group
DESCRIPTION
P re O perative Chemotherapy or Radiochemotherapy in E sophago-gastric Adenocarcinoma T rial POET. Michael Stahl on behalf of the German Oesophageal Cancer Study Group. German Oesophageal Cancer Study Group (GOeCSG). Kliniken Essen-Mitte University Clinic of Marburg - PowerPoint PPT PresentationTRANSCRIPT
Michael Stahlon behalf of the
German Oesophageal Cancer Study Group
PreOperative Chemotherapy or Radiochemotherapy in Esophago-
gastric Adenocarcinoma TrialPOET
German Oesophageal Cancer Study GroupGerman Oesophageal Cancer Study Group(GOeCSG)(GOeCSG)
Kliniken Essen-MitteKliniken Essen-MitteUniversity Clinic of MarburgUniversity Clinic of MarburgUniversity Clinic of TuebingenUniversity Clinic of TuebingenUniversity Clinic of DresdenUniversity Clinic of DresdenAlfried Krupp Krankenhaus EssenAlfried Krupp Krankenhaus EssenUniversity Clinic of DuesseldorfUniversity Clinic of DuesseldorfUniversity Clinic of EssenUniversity Clinic of EssenStädt. Klinikum KrefeldStädt. Klinikum KrefeldUniversity Clinic of BonnUniversity Clinic of BonnKrankenhaus St. Georg, LeipzigKrankenhaus St. Georg, LeipzigKaiserswerther Diakonie DüsseldorfKaiserswerther Diakonie DüsseldorfMarienhospital DüsseldorfMarienhospital DüsseldorfKlinikum Nürnberg NordKlinikum Nürnberg NordKlinikum KasselKlinikum KasselKlinikum OldenburgKlinikum OldenburgKatholische Kliniken im Kreis KleveKatholische Kliniken im Kreis KleveKnappschaft-Krankenhaus BottropKnappschaft-Krankenhaus BottropPhillippus-Stift EssenPhillippus-Stift EssenAsklepios-Kliniken Bad OldeslohAsklepios-Kliniken Bad Oldesloh
Eligibility CriteriaEligibility Criteria
Adenocarcinoma of the esophago-gastric Adenocarcinoma of the esophago-gastric junction (type I – III according to the Siewert junction (type I – III according to the Siewert classification)classification)
Locally advanced stage uT3-T4 NX M0 (CT Locally advanced stage uT3-T4 NX M0 (CT and EUS mandatory, diagnostic laparoscopy and EUS mandatory, diagnostic laparoscopy to detect peritoneal carcinosis, no PET)to detect peritoneal carcinosis, no PET)
POETGOeCSG
RationaleRationale
Preoperative CTX will be a standard of carePreoperative CTX will be a standard of careAdditional radiotherapy may increase rate of Additional radiotherapy may increase rate of R0-resection, rate of pN0, and rate of major R0-resection, rate of pN0, and rate of major histologic response (phase II trial of the histologic response (phase II trial of the group)group)This may increase the number of long term This may increase the number of long term survivorssurvivors
POETGOeCSG
StatisticsStatistics
Additional radiotherapy will increase 3-year Additional radiotherapy will increase 3-year survival from 25% to 35% survival from 25% to 35%
177 evaluable patients per arm needed 177 evaluable patients per arm needed (alpha level 5%, power 80%)(alpha level 5%, power 80%)
Stratification was done for center, type of Stratification was done for center, type of AC, uT-stage, weight loss, and genderAC, uT-stage, weight loss, and gender
POETGOeCSG
EndpointsEndpoints
Primary endpointPrimary endpoint- Overall survivalOverall survival
Secondary endpointsSecondary endpoints- Rate of R0-ResectionRate of R0-Resection- Rate of PCRRate of PCR- Postoperative MortalityPostoperative Mortality- Local tumor controlLocal tumor control
POETGOeCSG
RecruitmentRecruitment
Opened to accrualOpened to accrual December 2000December 2000Planned interim analysis Planned interim analysis October 2005October 2005Closed due to poor accrualClosed due to poor accrual December 2005December 2005
126 pts. randomized after stratification126 pts. randomized after stratification119 pts. eligible and evaluated119 pts. eligible and evaluatedArm A (CTX + S) Arm A (CTX + S) 59 pts.59 pts.Arm B (CTX + CRTX + S)Arm B (CTX + CRTX + S) 60 pts.60 pts.
POETGOeCSG
TreatmentTreatment
Arm AArm A
WeekWeek
Arm BArm B
POETGOeCSG
PLF I PLF III (3 weeks)
15 x 2 Gy in 3 weeks
PE (1 week)
Surgery
Surgery
1 1314 17 20-21
PLF: Cisplatin 50mg/m2, 1h, d 1,15,29. Leukovorin/5-FU 500mg/m2 2h / 2g/m2 24h, d 1,8,15,22,29,36PE: Cisplatin 50 mg/m2, 1h, d 2+8. Etoposide 80 mg/m2, 1h, d 3-5
PLF II
6 7
PLF I PLF II
Typical Radiation Field in Typical Radiation Field in EGJ-Cancer Type IEGJ-Cancer Type I
POETGOeCSG
Patient CharacteristicsPatient Characteristics
Arm AArm A Arm BArm B (N=59)(N=59) (N=60) (N=60)
uT3 / T4uT3 / T4 54 / 554 / 5 55 / 555 / 5
AEG I / II-IIIAEG I / II-III 32 / 2732 / 27 33 / 2733 / 27
Weight loss </>10%Weight loss </>10% 43 / 1643 / 16 44 /1644 /16
Male / femaleMale / female 54 / 554 / 5 54 / 654 / 6
WHO PSWHO PS 0 / 10 / 1 38 / 1738 / 17 # # 33 / 24 33 / 24 ##
Age (years)Age (years) 56.056.0 60.6 *60.6 *
POETGOeCSG
* Mann-Whitney p = 0.005# unknown in 7 pts.
Compliance to TreatmentCompliance to Treatment
Arm A Arm A Arm BArm B
Started treatmentStarted treatment (n)(n) 59 59 59 59
Completed part 1 Completed part 1 73% 73% 70% 70%
Completed part 2Completed part 2 66% 66% 70% 70%
Underwent surgeryUnderwent surgery 88% 88% 83% 83%
POETGOeCSG
Results at SurgeryResults at Surgery
Arm AArm A Arm B Arm B (n=59)(n=59) (n=60)(n=60)
Patients with SPatients with S 88.1%88.1% 81.7%81.7%
R0-ResectionR0-Resection 69.5%69.5% 71.7%71.7%
R1/R2R1/R2 13.6%13.6% 3.3% 3.3%
ExplorationExploration (n)(n) 3 3 4 4
peritoneal mets 2 peritoneal peritoneal mets 3mets 3
unresect. 1unresect. 1 hepatic mets 1 hepatic mets 1
POETGOeCSG
Pathohistologic Results
Arm AArm A Arm B p Arm B p (n=49)(n=49) (n=45)(n=45)
T0N0M0 T0N0M0 2.0% 2.0% 15.6% 15.6% 0.030.03T1-4N0M0T1-4N0M0 34.7% 34.7% 48.9% 48.9%T0-4N0M0 T0-4N0M0 36.7% 36.7% 64.4% 64.4% 0.010.01T0-4N+M0T0-4N+M0 55.1 55.1%% 31.1% 31.1%T1-4N+M1T1-4N+M1 8.2% 8.2% 4.4% 4.4%
POETGOeCSG
Mortality after Surgery
Arm AArm A Arm B Arm B (n=52)(n=52) (n=49) (n=49)
Hospital mortalityHospital mortality 2 (3.8%)2 (3.8%) 5 (10.2%)* 5 (10.2%)*
PneumoniaPneumonia 11 2 2
Anastom. leakageAnastom. leakage 11 2 2
Kardiac shockKardiac shock 00 1 1
POETGOeCSG
* Fisher´s exact p = 0.26
Overall SurvivalOverall Survival
Logrank p = 0.07HR Arm B vs. A0.67 (0.41-1.07)
Arm B
Arm A
POETGOeCSG
Follow-up 45.6 mo
47.4%
27.7%
Freedom from Local Tumor Freedom from Local Tumor ProgressionProgression
Logrank p = 0.06HR Arm B vs. A0.45 (0.19 -1.05)
POETGOeCSG
76.5%
59.0%
Arm B
Arm A
SurvivalSurvival
Arm AArm A Arm BArm B DifferenceDifference
2 year survival2 year survival 43.1%43.1% 61.9%61.9% 18.8%18.8%
3 year survival3 year survival 27.7%27.7% 47.4%47.4% 19.7%19.7%
(14.7-42.3) (14.7-42.3) (32.8-60.7)(32.8-60.7)
Median survivalMedian survival 21.1 mo21.1 mo 33.1 mo33.1 mo 12 mo12 mo
Median follow-upMedian follow-up 45.2 mo45.2 mo 46.2 mo46.2 mo 1 mo 1 mo
POETGOeCSG
POET - ConclusionsPOET - Conclusions
There is a strong trend for improved survival by There is a strong trend for improved survival by adding radiotherapy to preoperative chemotherapyadding radiotherapy to preoperative chemotherapy
Statistical significance was not reached in our trial Statistical significance was not reached in our trial due to low number of patients randomizeddue to low number of patients randomized
These results are in line with other published These results are in line with other published phase II-III trials investigating perioperative phase II-III trials investigating perioperative chemoradiation in EG-junction cancerchemoradiation in EG-junction cancer
POETGOeCSG